[go: up one dir, main page]

FI932282L - Protein c-derivat - Google Patents

Protein c-derivat Download PDF

Info

Publication number
FI932282L
FI932282L FI932282A FI932282A FI932282L FI 932282 L FI932282 L FI 932282L FI 932282 A FI932282 A FI 932282A FI 932282 A FI932282 A FI 932282A FI 932282 L FI932282 L FI 932282L
Authority
FI
Finland
Prior art keywords
protein
derivatives
Prior art date
Application number
FI932282A
Other languages
English (en)
Other versions
FI932282A7 (fi
FI932282A0 (fi
Inventor
Bruce Edward Gerlitz
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI932282A0 publication Critical patent/FI932282A0/fi
Publication of FI932282L publication Critical patent/FI932282L/fi
Publication of FI932282A7 publication Critical patent/FI932282A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI932282A 1992-05-21 1993-05-19 Proteiini C-johdannaisia FI932282A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (3)

Publication Number Publication Date
FI932282A0 FI932282A0 (fi) 1993-05-19
FI932282L true FI932282L (fi) 1993-11-22
FI932282A7 FI932282A7 (fi) 1993-11-22

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932282A FI932282A7 (fi) 1992-05-21 1993-05-19 Proteiini C-johdannaisia

Country Status (23)

Country Link
US (1) US5453373A (fi)
EP (1) EP0575054B1 (fi)
JP (1) JP3564150B2 (fi)
KR (1) KR100291529B1 (fi)
CN (1) CN1080658A (fi)
AT (1) ATE286121T1 (fi)
AU (1) AU661901B2 (fi)
BR (1) BR9301944A (fi)
CA (1) CA2096604C (fi)
CZ (1) CZ286016B6 (fi)
DE (1) DE69333727T2 (fi)
DK (1) DK0575054T3 (fi)
ES (1) ES2233925T3 (fi)
FI (1) FI932282A7 (fi)
HU (1) HU218408B (fi)
IL (1) IL105757A0 (fi)
MX (1) MX9302917A (fi)
MY (1) MY110664A (fi)
NO (1) NO311299B1 (fi)
NZ (1) NZ247651A (fi)
PH (1) PH29911A (fi)
PT (1) PT575054E (fi)
RU (1) RU2122004C1 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US6162629A (en) 1997-04-28 2000-12-19 Eli Lilly And Company Methods for processing activated protein C
ID23908A (id) * 1997-06-05 2000-05-25 Lilly Co Eli Metode pengobatan dari penyakit trombosis
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CA2338766A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company Cryogranulation of activated protein c
EP1124573A1 (en) 1998-10-22 2001-08-22 Eli Lilly And Company Methods for treating sepsis
AU1477000A (en) 1998-11-13 2000-06-05 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
ES2195655T3 (es) 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
ATE232739T1 (de) 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
EP1237917A2 (en) * 1999-11-19 2002-09-11 Eli Lilly And Company Protein c derivatives
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
JP2003521938A (ja) * 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
IL154999A0 (en) * 2000-10-18 2003-10-31 Maxygen Aps Protein c or activated protein c-like molecules
WO2002032461A2 (en) * 2000-10-18 2002-04-25 Maxygen Aps Protein c or activated protein c-like molecules
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
WO2003106666A2 (en) * 2002-06-14 2003-12-24 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
CA2602793C (en) * 2005-04-13 2016-11-22 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
ATE520414T1 (de) * 2007-06-18 2011-09-15 Univ Oregon Health & Science Protein c zur verwendung bei der aufrechterhaltung der hämostase
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
AU2009329493B2 (en) 2008-12-19 2014-09-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
AU2015246656B2 (en) 2014-04-16 2020-06-18 Zz Biotech Llc Use of APC analogue for wound healing
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1637807A1 (ru) * 1984-04-10 1991-03-30 Полтавский медицинский стоматологический институт Средство дл индивидуальной профилактики венерических заболеваний у мужчин
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
ATE286121T1 (de) 2005-01-15
NZ247651A (en) 1995-03-28
CN1080658A (zh) 1994-01-12
CZ94893A3 (en) 1994-01-19
JPH0680698A (ja) 1994-03-22
US5453373A (en) 1995-09-26
CA2096604C (en) 2003-12-16
MX9302917A (es) 1993-11-01
RU2122004C1 (ru) 1998-11-20
NO931840D0 (no) 1993-05-19
MY110664A (en) 1999-01-30
IL105757A0 (en) 1993-09-22
FI932282A7 (fi) 1993-11-22
HU9301461D0 (en) 1993-09-28
HUT69615A (en) 1995-09-28
DK0575054T3 (da) 2005-04-25
FI932282A0 (fi) 1993-05-19
KR100291529B1 (ko) 2001-06-01
KR930023370A (ko) 1993-12-18
AU3869993A (en) 1993-11-25
JP3564150B2 (ja) 2004-09-08
PH29911A (en) 1996-09-16
CA2096604A1 (en) 1993-11-22
NO311299B1 (no) 2001-11-12
EP0575054B1 (en) 2004-12-29
ES2233925T3 (es) 2005-06-16
DE69333727D1 (de) 2005-02-03
CZ286016B6 (cs) 1999-12-15
HU218408B (hu) 2000-08-28
EP0575054A3 (en) 1995-04-19
PT575054E (pt) 2005-03-31
BR9301944A (pt) 1993-11-30
NO931840L (no) 1993-11-22
AU661901B2 (en) 1995-08-10
DE69333727T2 (de) 2005-12-15
EP0575054A2 (en) 1993-12-22

Similar Documents

Publication Publication Date Title
FI932282L (fi) Protein c-derivat
DK91192D0 (da) Protein
FI930208L (fi) Kinazolinderivat
FI935431A7 (fi) Kiantsoliinijohdannaisia
FI980341A7 (fi) 2-oksi-indolijohdannaisia
ATA75293A (de) Indolderivate
FI933037A7 (fi) Tiazolylvinylfenylderivat
FI941398L (fi) Modifioituja peptidijohdannaisia
DE69230727D1 (de) Neuartige peptidderivate
FI941423A7 (fi) 17beta-substituoidut 4-atsa-5alfa-androstan-3-onijohdannaiset
FI933001L (fi) Antigastrit-aemne
FI944412L (fi) Proteiinin puhdistus
DK19991D0 (da) Proteinpraeparationer
FI952574A7 (fi) Glykosyylitransferaasiaktiiviset proteiinit
DE69330497D1 (de) Chinazolin-derivate
FI20010214L (fi) Asyyliaminoindolijohdannaisia
FI945416L (fi) Dolastatiinijohdannaisia
DK132892D0 (da) Proteiner
DE59308714D1 (de) Cyclobutan-benzol-derivate
FI20002460A7 (fi) 4-difenyylimetyylipiperidiinijohdannaisia
FI934588A0 (fi) Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben
NO952288D0 (no) Benzazepinon-derivater
FI923311L (fi) Proteiner
DE69313890D1 (de) 5-Aminoflavon-Derivate
FI930367L (fi) Puridinderivat